Summary

Summary

• The rapid spread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the declaration of a global pandemic barely three months after emerging.
• A majority of patients presenting with coronavirus disease 2019 (COVID-19) will experience a mild illness that can largely be managed in the community. Patients with moderate illness or with risk factors for progressive disease require careful monitoring  and early referral to hospital for any signs of clinical deterioration.
• Increasing age and the presence of co-morbidities are associated with more severe disease and poor outcomes
• Treatment for COVID-19 is currently supportive, with appropriate management of respiratory dysfunction the cornerstone of care.
• No good clinical evidence for any specific therapies (including antiviral and immune modulating agents) currently exists. Investigational therapies for COVID-19 should be used only in approved, randomized, controlled trials